公开(公告)号：US20250045926A1

公开(公告)日：2025-02-06

申请号：US18776651

申请日：2024-07-18

Applicant: BAYER AKTIENGESELLSCHAFT

Inventor： Matthias LENGA ,  Ivo Matteo BALTRUSCHAT

IPC: G06T7/00 ,  A61B5/055 ,  A61B6/03 ,  A61K49/10 ,  G06T11/00 ,  G06V10/774 ,  G06V10/776

Abstract: The present disclosure relates to the technical field of generation of synthetic images, in particular synthetic medical images. The subjects of the present disclosure are a method, a computer system and a computer-readable storage medium comprising a computer program for detecting artifacts in synthetic images, in particular synthetic medical images.

公开(公告)号：US12173087B2

公开(公告)日：2024-12-24

申请号：US17582368

申请日：2022-01-24

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Robert J. Gillies ,  David L. Morse ,  Natalie M. Barkey ,  Kevin N. Sill ,  Josef Vagner ,  Narges K. Tafreshi ,  Jonathan L. Sessler ,  Christian Preihs ,  Victor J. Hruby

IPC: C07K14/00 ,  A61K47/64 ,  A61K47/69 ,  A61K49/00 ,  A61K49/10 ,  A61K49/18 ,  C07K5/117 ,  C07K7/08 ,  C07K14/68 ,  C07K14/72 ,  A61K38/34

Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imagable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：US20240366801A1

公开(公告)日：2024-11-07

申请号：US18683962

申请日：2022-08-16

Applicant: CAMBRIDGE ENTERPRISE LIMITED

Inventor： Arnaud COMMENT ,  Adam GAUNT ,  Jennifer Sunari LEWIS ,  Irene MARCO-RIUS ,  Tian CHENG

IPC: A61K49/10 ,  A61K49/18

Abstract: In a method for preparing a hyperpolarised sample, for example for a magnetic resonance procedure, a starting solution comprising alpha-ketoglutaric acid and 13C-labelled molecules is frozen to form a frozen solution. The solution is irradiated with ultraviolet and/or visible radiation, to generate free radicals. The frozen solution is then hyperpolarised by applying a magnetic field to the solution while irradiating it with frequency-modulated microwave radiation.

公开(公告)号：US20240361407A1

公开(公告)日：2024-10-31

申请号：US18764964

申请日：2024-07-05

Applicant: NVISION IMAGING TECHNOLOGIES GMBH

Inventor： Ilai SCHWARTZ ,  Anna PARKER ,  Stephan KNECHT ,  Tim EICHHORN ,  John BLANCHARD

IPC: G01R33/36 ,  A61K49/10 ,  B01D11/04

CPC classification number: G01R33/3628 ,  A61K49/10 ,  B01D11/04

Abstract: Systems and methods are disclosed for increasing a nuclear spin polarization of a target compound. In accordance with such systems and methods, a first non-thermal equilibrium nuclear spin polarization can be imparted to at least one source atom of a source compound, the source atom having a nuclear gyromagnetic ratio of at least 12 megahertz per tesla (MHz/T). A first solution can be obtained that includes the source compound and a target compound. The at least one source atom can be present in a source concentration of at least 0.1 molar (M) in the first solution. A second non-thermal equilibrium nuclear spin polarization of at least 0.01% can be imparted to the at least one target atom of the target compound via a nuclear Overhauser effect (NOE) transfer of the first non-thermal equilibrium nuclear spin polarization to the at least one target atom.

公开(公告)号：US20240350678A1

公开(公告)日：2024-10-24

申请号：US18687044

申请日：2022-08-26

Applicant: NVISION IMAGING TECHNOLOGIES GMBH

Inventor： Ilai SCHWARTZ ,  Michael KEIM ,  Stephan KNECHT

IPC: A61K49/10 ,  C07B59/00

CPC classification number: A61K49/10 ,  C07B59/001 ,  C07B2200/05

Abstract: The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes precursor compounds for use in producing hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications.

公开(公告)号：US20240251658A1

公开(公告)日：2024-07-25

申请号：US18287129

申请日：2021-12-01

Applicant: BeeOLED GmbH

Inventor： Carsten ROTHE ,  Volodymyr SENKOVSKYY

IPC: H10K85/30 ,  A61B5/055 ,  A61K49/10 ,  C07F5/00 ,  C09K11/02 ,  C09K11/06 ,  G01R33/56 ,  H10K50/11 ,  H10K71/10 ,  H10K71/16 ,  H10K85/10

CPC classification number: H10K85/351 ,  A61K49/101 ,  C07F5/003 ,  C09K11/02 ,  C09K11/06 ,  H10K71/16 ,  H10K71/191 ,  H10K85/10 ,  A61B5/055 ,  C09K2211/1007 ,  C09K2211/1044 ,  C09K2211/1074 ,  C09K2211/1096 ,  C09K2211/182 ,  G01R33/5601 ,  H10K50/11

Abstract: A metal-organic coordination compound, which is neutrally charged and wherein the coordination compound comprises at least one divalent lanthanide coordinated by a cyclic organic ligand, wherein the cyclic organic ligand contains two monoanionic groups covalently linked with the cyclic organic ligand and being separated from each other by a sequence of at least two intervening atoms.

公开(公告)号：US20240225448A1

公开(公告)日：2024-07-11

申请号：US18559323

申请日：2022-04-28

Applicant: Bayer Aktiengesellschaft

Inventor： Gunnar SCHUETZ ,  Gesine KNOBLOCH

IPC: A61B5/00 ,  A61B5/055 ,  A61K49/10 ,  G01R33/56

CPC classification number: A61B5/004 ,  A61B5/055 ,  A61B5/4244 ,  A61K49/103 ,  G01R33/5601 ,  G01R33/5608

Abstract: The invention relates to the technical field of characterising lesions in the liver using dynamic contrast-enhanced magnetic resonance tomography.

公开(公告)号：US20240199588A1

公开(公告)日：2024-06-20

申请号：US18550178

申请日：2022-03-21

Applicant: The Hong Kong Polytechnic University

Inventor： Ga-Lai LAW

IPC: C07D403/14 ,  A61K49/00 ,  A61K49/10 ,  A61K51/04 ,  C07D255/02 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K49/0002 ,  A61K49/106 ,  A61K51/0482 ,  C07D255/02 ,  C07D401/14

Abstract: Cyclic 1,4,7-triazacyclononane-1,4,7-triacetic acid chelators and metal complexes comprising the same useful as positron emission tomography imaging agents, magnetic resonance imaging contrast agents, and computed tomography imaging agents, and optical imaging agents, and methods of use and preparation thereof.

公开(公告)号：US11931428B2

公开(公告)日：2024-03-19

申请号：US16947869

申请日：2020-08-21

Applicant: Wake Forest University Health Sciences

Inventor： John C. Lukesh, III

IPC: C07F11/00 ,  A61K9/00 ,  A61K49/00 ,  A61K49/10

CPC classification number: A61K49/0039 ,  A61K9/0019 ,  A61K9/0053 ,  C07F11/00

Abstract: Provided herein is a compound of formula I:




and the use thereof for detecting the presence of hydrogen sulfide in cells or tissues in vitro or in vivo. The detecting may be useful, for example, in diagnosing cancer or other diseases related to imbalanced hydrogen sulfide (H2S) production such as neurodegenerative diseases.

公开(公告)号：US20230414791A1

公开(公告)日：2023-12-28

申请号：US18463450

申请日：2023-09-08

Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED

Inventor： Ayelet GAMLIEL ,  Talia HARRIS ,  Gal SAPIR ,  Jacob SOSNA ,  Moshe John GOMORI ,  Rachel KATZ-BRULL

IPC: A61K49/10 ,  A61B5/055 ,  G01R33/56 ,  G01R33/563

CPC classification number: A61K49/10 ,  A61B5/055 ,  G01R33/5601 ,  G01R33/56366

Abstract: The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.